



ASX Release

Correction of Clerical Error re Outcome of Mediation

Sydney, Friday 28 July 2017

In the ASX announcement dated 27 July 2017, Memphasys Ltd (“**Memphasys**”) erroneously reported that PrIME Biologics Private Limited (“**Prime**”) and Pulau Manukan Ventures Labuan Ltd (“**Manukan**”) will no longer pursue any claim against Memphasys in relation to the SGD4.8m debt associated with certain equipment at the Prime facility in Singapore.

Due to a clerical error, Memphasys inadvertently included the words “*associated with certain equipment at the PrIME facility in Singapore*”. The sentence should have read: “Prime and Manukan will no longer pursue any claim against Memphasys in relation to the SGD4.8m debt.”

For further information please contact:

Alison Coutts
Executive Chairman
+61 2 8415 7300
alison.coutts@memphasys.com

About Memphasys:

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.

Memphasys Limited
30-32 Richmond Road
Homebush West NSW 2140

Postal Address
P.O. Box 2202
Homebush West NSW 2140

Contact Details
P +612 8415 7300
F +612 8415 7399

E info@memphasys.com
W memphasys.com
ABN 33 120 047 556